PegBio Co

PegBio Co Net Change in Cash

The Net Change in Cash of PegBio Co (2565.HK) as of Nov 18, 2026 is 444.90 M CNY. In the previous year, Net Change in Cash was -48.76 M CNY — a change of -1,012.52% (higher).

Net Change in Cash

444.90 MCNY

YoY

-1,012.52%

Last updated:

Net Change in Cash of PegBio Co is 2025 444.90 M CNY. Net Change in Cash of PegBio Co was 2024 -48.76 M CNY. It decreases by -1,012.52% higher compared to the previous year.

The PegBio Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2022
-171.37 M CNY
Jan 1, 2023
16.85 M CNY
Jan 1, 2024
-48.76 M CNY
Jan 1, 2025
444.90 M CNY
The PegBio Co Net Change in Cash history
YEARNet Change in CashYoY
444.90 MCNY-1,012.52%
-48.76 MCNY-389.35%
16.85 MCNY-109.83%
-171.37 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Net Change in Cash of PegBio Co is 444.90 M CNY in 2025.

Net Change in Cash of PegBio Co changed from -48.76 M CNY to 444.90 M CNY, representing a -1,012.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash PegBio Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PegBio Co

All Key Metrics — PegBio Co